Ultrasensitive quantitation of FLT3-ITD mutation in patients with acute myeloid leukemia using ddPCR.
AML
FLT3-ITD
Fragment analysis
ddPCR
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
28
10
2022
accepted:
17
05
2023
medline:
26
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
ppublish
Résumé
FLT3-ITD mutations occur in 45-50% of cytogenetically normal AML patients. Conventional fragment analysis using capillary electrophoresis is routinely used to quantitate FLT3-ITD mutations. Fragment analysis however has limited sensitivity. Here, FLT3-ITD was quantified in AML patients using an in-house developed ultra-sensitive droplet digital polymerase chain reaction assay (ddPCR). The allelic ratio of FLT3-ITD was also absolutely measured by both Fragment analysis and ddPCR. The sensitivity of ddPCR in quantitation of FLT3-ITD mutation was superior to Fragment analysis. This study demonstrates the feasibility of using the described in-house ddPCR method to quantify the FLT3-ITD mutation and measure FLT3-ITD AR in AML patients.
Sections du résumé
BACKGROUND
BACKGROUND
FLT3-ITD mutations occur in 45-50% of cytogenetically normal AML patients. Conventional fragment analysis using capillary electrophoresis is routinely used to quantitate FLT3-ITD mutations. Fragment analysis however has limited sensitivity.
METHODS AND RESULTS
RESULTS
Here, FLT3-ITD was quantified in AML patients using an in-house developed ultra-sensitive droplet digital polymerase chain reaction assay (ddPCR). The allelic ratio of FLT3-ITD was also absolutely measured by both Fragment analysis and ddPCR. The sensitivity of ddPCR in quantitation of FLT3-ITD mutation was superior to Fragment analysis.
CONCLUSION
CONCLUSIONS
This study demonstrates the feasibility of using the described in-house ddPCR method to quantify the FLT3-ITD mutation and measure FLT3-ITD AR in AML patients.
Identifiants
pubmed: 37300744
doi: 10.1007/s11033-023-08534-x
pii: 10.1007/s11033-023-08534-x
doi:
Substances chimiques
Nuclear Proteins
0
Nucleophosmin
117896-08-9
fms-Like Tyrosine Kinase 3
EC 2.7.10.1
FLT3 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6097-6105Subventions
Organisme : Iran University of Medical Sciences
ID : 14651
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Desai P, Mencia-Trinchant N, Savenkov O et al (2018) Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. https://doi.org/10.1038/s41591-018-0081-z
doi: 10.1038/s41591-018-0081-z
pubmed: 29988143
pmcid: 6849383
Garg M, Nagata Y, Kanojia D et al (2015) Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. https://doi.org/10.1182/blood-2015-05-646240
doi: 10.1182/blood-2015-05-646240
pubmed: 26438511
pmcid: 4661172
Mrózek K, Marcucci G, Paschka P et al (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109:431
doi: 10.1182/blood-2006-06-001149
pubmed: 16960150
pmcid: 1785102
Pratz KW, Levis M (2017) How I treat FLT3-mutated AML. Blood. https://doi.org/10.1182/blood-2016-09-693648
doi: 10.1182/blood-2016-09-693648
pubmed: 27872057
pmcid: 5290983
Levis M (2013) FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology 2013:220
doi: 10.1182/asheducation-2013.1.220
pubmed: 24319184
Papaemmanuil E, Gerstung M, Bullinger L et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. https://doi.org/10.1056/NEJMoa1516192
doi: 10.1056/NEJMoa1516192
pubmed: 27579651
pmcid: 4979995
Kim Y, Lee GD, Park J et al (2015) Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length. Blood Cancer J 5:e336–e336. https://doi.org/10.1038/bcj.2015.61
doi: 10.1038/bcj.2015.61
pubmed: 26832846
pmcid: 4558586
Sakaguchi M, Yamaguchi H, Najima Y et al (2018) Prognostic impact of low allelic ratio FLT3-ITD and mutation in acute myeloid leukemia. Blood Adv. https://doi.org/10.1182/bloodadvances.2018020305
doi: 10.1182/bloodadvances.2018020305
pubmed: 30341082
pmcid: 6199656
Grob T, Meijer R, Kavelaars F et al (2016) Mutant NPM1 MRD and FLT3-ITD status are independent prognostic factors for the risk of relapse in AML patients. Clin Lymphoma, Myeloma Leuk 16:S31–S32. https://doi.org/10.1016/j.clml.2016.07.045
doi: 10.1016/j.clml.2016.07.045
Abdelhamid E, Preudhomme C, Helevaut N et al (2012) Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leuk Res. https://doi.org/10.1016/j.leukres.2011.11.002
doi: 10.1016/j.leukres.2011.11.002
pubmed: 22129478
Schuurhuis GJ, Heuser M, Freeman S et al (2018) Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party. Blood. https://doi.org/10.1182/blood-2017-09-801498
doi: 10.1182/blood-2017-09-801498
pubmed: 29669779
pmcid: 5865231
Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59–66. https://doi.org/10.1182/blood.v100.1.59
doi: 10.1182/blood.v100.1.59
pubmed: 12070009
Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Arber DA, Borowitz MJ, Cessna M et al (2017) Initial diagnostic workup of acute Leukemia guideline from the College of American pathologists and the American Society of Hematology. Arch Pathol Lab Med 141:1342
doi: 10.5858/arpa.2016-0504-CP
pubmed: 28225303
Abou Dalle I, Ghorab A, Patel K et al (2020) Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3-mutant acute myeloid leukemia. Blood Cancer J 10:48. https://doi.org/10.1038/s41408-020-0318-1
doi: 10.1038/s41408-020-0318-1
pubmed: 32366841
pmcid: 7198530
Nielsen LK, Kelly SS, Sola CBS et al (2009) Making sense of hematopoietic stem cell niches. Blood 5:1–12. https://doi.org/10.1182/blood-2014-09-570192
doi: 10.1182/blood-2014-09-570192
Kim H, Kim I-S, Chang CL et al (2019) T-cell receptor rearrangements determined using fragment analysis in patients with T-acute lymphoblastic leukemia. Ann Lab Med 39:125–132. https://doi.org/10.3343/alm.2019.39.2.125
doi: 10.3343/alm.2019.39.2.125
pubmed: 30430774
Patel JP, Gönen M, Figueroa ME et al (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. https://doi.org/10.1056/NEJMoa1112304
doi: 10.1056/NEJMoa1112304
pubmed: 23234517
pmcid: 3549418
Kojabad AA, Farzanehpour M, Galeh HEG et al (2021) Droplet digital PCR of viral DNA/RNA, current progress, challenges, and future perspectives. J Med Virol 93:4182–4197. https://doi.org/10.1002/jmv.26846
doi: 10.1002/jmv.26846
pubmed: 33538349
pmcid: 8013307
Voso MT, Ottone T, Lavorgna S et al (2019) MRD in AML: the role of new techniques. Front Oncol 9:655
doi: 10.3389/fonc.2019.00655
pubmed: 31396481
pmcid: 6664148
Franke G-N, Maier J, Wildenberger K et al (2020) Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia. J Mol Diagnostics 22:81–89. https://doi.org/10.1016/j.jmoldx.2019.08.007
doi: 10.1016/j.jmoldx.2019.08.007
Hindson CM, Chevillet JR, Briggs HA et al (2013) Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. https://doi.org/10.1038/nmeth.2633
doi: 10.1038/nmeth.2633
pubmed: 23995387
pmcid: 4118677
Whale AS, Huggett JF, Tzonev S (2016) Fundamentals of multiplexing with digital PCR. Biomol Detect Quantif 10:15
doi: 10.1016/j.bdq.2016.05.002
pubmed: 27990345
pmcid: 5154634
Panuzzo C, Jovanovski A, Ali MS et al (2022) Revealing the mysteries of acute myeloid leukemia: from quantitative PCR through next-generation sequencing and systemic metabolomic profiling. J Clin Med 11:483
doi: 10.3390/jcm11030483
pubmed: 35159934
pmcid: 8836582
Coltoff A, Houldsworth J, Keyzner A et al (2018) Role of minimal residual disease in the management of acute myeloid leukemia—a case-based discussion. Ann Hematol 97:1155
doi: 10.1007/s00277-018-3330-9
pubmed: 29704019
Qin D, Xia Y, Whitesides GM (2010) Soft lithography for micro- and nanoscale patterning. Nat Protoc 5:491–502. https://doi.org/10.1038/nprot.2009.234
doi: 10.1038/nprot.2009.234
pubmed: 20203666
Murphy KM, Levis M, Hafez MJ et al (2003) Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn. https://doi.org/10.1016/S1525-1578(10)60458-8
doi: 10.1016/S1525-1578(10)60458-8
pubmed: 14573780
pmcid: 1907340
Drandi D, Kubiczkova-Besse L, Ferrero S et al (2015) Minimal residual disease detection by droplet digital PCR in multiple myeloma, mantle cell lymphoma, and follicular lymphoma: a comparison with real-time PCR. J Mol Diagn. https://doi.org/10.1016/j.jmoldx.2015.05.007
doi: 10.1016/j.jmoldx.2015.05.007
pubmed: 26319783
Sakaguchi M, Yamaguchi H, Najima Y et al (2018) Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv 2:2744–2754. https://doi.org/10.1182/bloodadvances.2018020305
doi: 10.1182/bloodadvances.2018020305
pubmed: 30341082
pmcid: 6199656
Gomez-Arteaga A, Guzman ML (2018) Minimal residual disease in acute myeloid leukemia. Advances in experimental medicine and biology. Springer, Cham
Fröhling S, Schlenk RF, Breitruck J et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16–60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm. Blood 100:4372–4380. https://doi.org/10.1182/blood-2002-05-1440
doi: 10.1182/blood-2002-05-1440
pubmed: 12393388
Daver N, Schlenk RF, Russell NH, Levis MJ (2019) Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33:299
doi: 10.1038/s41375-018-0357-9
pubmed: 30651634
pmcid: 6365380
Sakaguchi M, Nakajima N, Yamaguchi H et al (2020) The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia. Leuk Res Rep 13:100198. https://doi.org/10.1016/j.lrr.2020.100198
doi: 10.1016/j.lrr.2020.100198
pubmed: 32368486
pmcid: 7184170
Lee G, Kim J, Lee S et al (2017) Fragment analysis for detection of the FLT3-internal tandem duplication: comparison with conventional PCR and Sanger sequencing. Lab Med Online 7:13. https://doi.org/10.3343/lmo.2017.7.1.13
doi: 10.3343/lmo.2017.7.1.13
Grunwald MR, Tseng L-H, Lin M-T et al (2014) Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia. Biol Blood Marrow Transplant 20:1989–1995. https://doi.org/10.1016/j.bbmt.2014.08.015
doi: 10.1016/j.bbmt.2014.08.015
pubmed: 25240816
pmcid: 4253693
Levis MJ, Perl AE, Altman JK et al (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv. https://doi.org/10.1182/bloodadvances.2018015925
doi: 10.1182/bloodadvances.2018015925
pubmed: 30190282
pmcid: 6134225
Zuffa E, Franchini E, Papayannidis C et al (2015) Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients. Oncotarget. https://doi.org/10.18632/oncotarget.5161
doi: 10.18632/oncotarget.5161
pubmed: 26384303
pmcid: 4741605
Szczepański T, Willemse MJ, Brinkhof B et al (2002) Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B–ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 99:2315–2323. https://doi.org/10.1182/blood.V99.7.2315
doi: 10.1182/blood.V99.7.2315
pubmed: 11895762
van Dongen JJM, Langerak AW, Brüggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia 17:2257–2317. https://doi.org/10.1038/sj.leu.2403202
doi: 10.1038/sj.leu.2403202
pubmed: 14671650